Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

摘要: While cancer immune therapy has revolutionized the treatment of metastatic disease across a wide range diagnoses, major limiting factor remains with regard to relying on adequate homing anti-tumor effector cells tumor site both prior and after therapy. Adoptive cell transfer (ACT) autologous T have improved outlook patients melanoma. Prior approval checkpoint inhibitors, this strategy was most promising. However, while response rates up 50% been reported, is still rather crude. Thus, improvements are needed within reach. A hallmark developing evasion destruction. Achieved through recruitment suppressive subsets, upregulation inhibitory receptors development physical chemical barriers (such as poor vascularization hypoxia) leaves microenvironment hostile destination for cells. In paper, we review emerging strategies improving (TILs, CARs, TCR engineered cells, etc.) genetic engineering chemokine matching chemokines microenvironment. proven successful in several preclinical models moved into first phase I/II clinical trial humans, these studies show modest (doubling) increase infiltration which raises question whether road blocks must be tackled efficient homing. We propose role exercise modulating preparing platform time personalized medicine engineering, “old tool” may way augment efficacy depth